Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8452W HIGH $2.68
Volume
13.30 K
Value Traded
39.66 K
Short % Float
2.62%
-4.96%Week
-21.18%1 Month
+15.52%3 Month
+49.05%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.47 M
EPS (TTM)
-1.89
P/E Ratio
-
Ent. Value
-1.12 M
Total Shares
4.83 M
Float Shares
4.70 M
Insiders
2.66%
Institutions
28.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ALZN Catalyst Timeline
Dated clinical, regulatory and corporate events for Alzamend Neuro, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alzamend Neuro, Inc.
119Total events
2Upcoming
15Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidancePresentation
Deadline granted by Nasdaq for Alzamend to regain compliance with the Equity Rule
▲Quarterly UpdateCorporate
Alzamend regains compliance with Nasdaq Listing Rule 5550(b)(1) Equity Rule
●Quarterly UpdateCorporate
Alzamend filed Form 10-Q for quarter ended July 31, 2026 showing stockholders' equity of $5,802,680
▼Equity OfferingCorporate
Initial closing of $7.5 million tranche of Series D Convertible Preferred Stock
◆Equity OfferingCorporate
Second tranche of $2.5 million expected to close within ten business days after resale registration statement declared effective
●Timing GuidancePresentation
Deadline for Alzamend to submit plan to regain compliance with Nasdaq Equity Rule
▼Quarterly UpdateCorporate
Nasdaq notified Alzamend it did not meet minimum market value of listed securities requirement
●Topline ReadoutAL001Clinical Data
AL001 healthy human cohort topline data reported
healthy human cohortsource ↗
◆Topline ReadoutAL001Clinical Data
Topline data expected from Phase II study of AL001
Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disordersource ↗
▲Trial CompletionAL001Trial
AL001 healthy human cohort completed its clinical portion
healthy human cohortsource ↗
◆Trial InitiationAL001Trial
Initiation of Phase II clinical trial of AL001 for PTSD at Massachusetts General Hospital
post-traumatic stress disordersource ↗
◆Poster PresentationAL001Presentation
Poster presentation at MHSRS 2025 on AL001 vs lithium carbonate brain-to-plasma exposure in PTSD subjects
PTSDsource ↗
◆Trial InitiationAL001Trial
Phase II clinical trial of AL001 for bipolar disorder expected to commence
bipolar disordersource ↗
▼Equity OfferingCorporate
Investor accelerated purchase of additional $4M Preferred Stock, completing financing
▲First Patient DosedAL001Trial
First patient dosed in Phase II clinical trial of AL001 in healthy human subjects
Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disordersource ↗
▲First Patient DosedAL001Trial
First patient enrolled in Phase II clinical study of AL001 in healthy subjects
Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disordersource ↗
▲Trial InitiationAL001Trial
Initiation of first Phase II clinical study of AL001 in healthy subjects
Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disordersource ↗
▲Partnership / LicenseCorporate
Alzamend partners with QMENTA for AI-powered imaging in Phase II trials of AL001
▲Trial InitiationAL001Trial
Initiation of first Phase II clinical study of AL001 in healthy human subjects
Alzheimer's disease, bipolar disorder, major depressive disorder, PTSDsource ↗
▲First Patient DosedAL001Trial
AL001 healthy human cohort initiated in partnership with Massachusetts General Hospital
healthy human cohortsource ↗
◆Trial InitiationAL001Trial
First Phase II clinical study of AL001 expected to commence in Q2 2025
healthy human subjectssource ↗
▼Equity OfferingCorporate
Entered into Securities Purchase & Exchange Agreement for up to $5M financing
●Manufacturing MilestoneAL001CMC / Inspection
Specialized head coil for lithium brain imaging finalized
◆Topline ReadoutAL001Clinical Data
Topline data expected from Phase II study of AL001
Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disordersource ↗
◆Trial InitiationAL001Trial
Five Phase II trials of AL001 to be initiated in partnership with Massachusetts General Hospital
Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disordersource ↗
◆Trial InitiationALZN002Trial
Phase I/IIA trial of ALZN002 to resume following re-engagement of new CRO
Alzheimer's diseasesource ↗
◆Restructuring LayoffsCorporate
Nasdaq Hearings Panel grants extension to comply with Stockholder Equity Rule by September 23, 2024
▲Partnership / LicenseAL001Corporate
Teamed with Massachusetts General Hospital and Harvard Medical School for five Phase II imaging trials
Alzheimer's disease, bipolar disorder, major depressive disorder, post-traumatic stress disordersource ↗
▼Equity OfferingCorporate
Registered direct offering and concurrent private placement for up to $25 million
◆Trial InitiationALZN002Trial
Expected to resume Phase I/IIA clinical trial for ALZN002
Alzheimer's Diseasesource ↗
▼Trial PausedALZN002Trial
CRO terminated agreement; trial paused while seeking new CRO
Alzheimer's disease (mild to moderate)source ↗
▼Equity OfferingCorporate
Entered into securities purchase agreement for up to $25M preferred stock and warrants
◆Trial InitiationAL001Trial
Initiation of two Phase II clinical trials for mild to moderate Alzheimer's
Alzheimer's diseasesource ↗
▲FDA Feedback ReceivedAL001FDA Meeting
Received 'Study May Proceed' notification from FDA for Phase II PTSD trial
Post-Traumatic Stress Disordersource ↗
◆Reverse Stock SplitCorporate
Reverse stock split to be effected by November 1, 2023 to regain Nasdaq compliance
▲FDA Feedback ReceivedAL001FDA Meeting
Received 'Study May Proceed' notification from FDA for Phase II MDD trial
Major Depressive Disordersource ↗
▲FDA Feedback ReceivedALZN002FDA Meeting
Received 'Study May Proceed' notification from FDA for Phase II trial
Alzheimer's Diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How ALZN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | AL001 | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$3M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.4x
rNPV / MCap
Top 47%
Micro Cap(rank 311 of 660)
Percentile Rank
Alzamend Neuro, Inc. faces pipeline headwinds (37/100), with $200M risk-adjusted pipeline value, led by ALZN002 in Alzheimer Disease (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALZN002 Monoclonal antibodyNCT05834296 | Alzheimer Disease | Phase 1 | ACTIVE NOT_RECRUITING | 30 | Mar 3, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALZN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AL001 | Alzheimer's disease, bipolar disorder, major depressive disorder, PTSD | Phase 2a | 2023-06-22 | maximum tolerated dose (MTD) identified; lithium carbonate equivalent dose of 240 mg 3-times daily (TID)Read More | Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 Topline data identifies maximum tolerated dose from Phase IIA multiple ascending dose study as assessed by an independent safety review committRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| AULT MILTON C IIIDirector | Sell | -2,000 | $1.56 | 08/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALZN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ALZN for Q2 2026. | ||||
ALZN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALZN ranks across every disease it competes in
Competitive Position is a premium feature
See how ALZN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALZN News
ALZNAlzamend Neuro Regains Compliance with Nasdaq Listing Standards
Alzamend Neuro has regained compliance with Nasdaq listing standards, as confirmed by a notification letter from Nasdaq. The company demonstrated stockholders' equity of $5.8 million, exceeding the required minimum of $2.5 million. CEO Stephan Jackman highlighted the importance of maintaining the Nasdaq listing and expressed commitment to advancing their clinical trials for AL001 in partnership with Massachusetts General Hospital.
Read more →ALZN▲ +7.2%on this news
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Alzamend Neuro's Phase 1/2A clinical trial data for AL001 has been accepted for poster presentation at Neuroscience 2026. The study evaluates brain network changes associated with a novel lithium treatment using advanced imaging techniques. The findings could enhance the understanding of lithium's effects on brain connectivity and offer a safer alternative for treating various mental health conditions.
Read more →ALZNAlzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Alzamend Neuro announced that its Phase 1/2A lithium imaging data for AL001 has been accepted for oral presentation at the ISMRM Workshop in Barcelona. The presentation will detail pharmacokinetic imaging results from a clinical trial involving healthy subjects. This data could enhance understanding of lithium delivery to the brain, potentially improving treatment for various mental health disorders.
Read more →ALZN▲ +8.2%on this news
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Alzamend Neuro has closed an initial tranche of $7.5 million from a Securities Purchase Agreement with Ault Lending, part of a larger potential funding of $25 million. The funds will be used to support Alzamend's clinical programs, including trials for Alzheimer's disease and other mental health conditions. The agreement includes multiple tranche closings over the next months.
Read more →ALZNAlzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Alzamend Neuro has reported promising pharmacodynamic data from a Phase II trial of AL001, suggesting it may interact with the brain differently than lithium carbonate. The study indicates that AL001 could provide similar benefits to lithium while potentially offering better tolerability and fewer side effects. However, these findings are preliminary and require further validation in larger studies.
Read more →ALZN▼ -22.3%on this news· ran to -46% by day 1
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Alzamend Neuro announced positive topline results from its Phase II clinical trial of AL001, a novel lithium formulation. The study showed that AL001 achieved bioequivalence with standard lithium carbonate while demonstrating superior brain delivery across all measured regions. Additionally, AL001 reached peak brain concentrations faster, suggesting potential benefits for therapeutic onset. A second Phase II trial is already in progress.
Read more →ALZNAlzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Alzamend Neuro has launched a Phase II clinical trial for AL001, a novel lithium delivery system, targeting patients with bipolar disorder type 1. Conducted in collaboration with Massachusetts General Hospital, the trial aims to compare AL001 with traditional lithium carbonate. Topline data is expected by Q3 2026, following promising results from prior studies.
Read more →ALZN▼ -5.3%on this news· ran to -19% by day 1
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Alzamend Neuro has completed the clinical portion of its Phase II trial for AL001, a novel lithium delivery system, at Massachusetts General Hospital. The trial aims to evaluate AL001's effectiveness compared to traditional lithium carbonate. The company anticipates topline data in the first quarter of 2026, which may inform future trials for Alzheimer's and other disorders. AL001 could transform treatment by reducing the need for therapeutic drug monitoring.
Read more →ALZN▼ -6.4%on this news· ran to -24% by day 3
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro, a clinical-stage biopharmaceutical company, will present a poster at the Military Health System Research Symposium from August 4-7, 2025. The presentation will focus on the differences in lithium exposure in PTSD subjects between AL001 and lithium carbonate. This research aims to improve treatment strategies for various mental health disorders, including Alzheimer's and PTSD.
Read more →ALZN▼ -5.9%on this newsshared move
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro reported its annual financial results and provided updates on its clinical programs, highlighting a successful $5 million financing deal completed ahead of schedule. The company is advancing its lead drug candidate, AL001, through five Phase II clinical trials in collaboration with prestigious institutions. However, it faces challenges in securing a new contract research organization for its secondary candidate, ALZN002.
Read more →ALZNAlzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Alzamend Neuro has successfully completed a $5 million private placement, finalizing the deal months ahead of schedule. The funds will support five Phase II clinical trials for its lead candidate, AL001, targeting Alzheimer's disease and other mental health disorders. The first trial has already commenced, with topline data expected by the end of 2025.
Read more →ALZN▲ +63.9%on this news
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro has announced the dosing of the first patient in its Phase II clinical trial for AL001, a novel lithium delivery system. Conducted at Massachusetts General Hospital, this trial aims to evaluate AL001's effectiveness in delivering lithium more effectively to the brain while minimizing systemic side effects. The study could lead to improved treatment options for patients with Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD.
Read more →ALZN▲ +5.9%on this news
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro has enrolled its first patient in a Phase II clinical trial for AL001, a novel lithium delivery system aimed at improving treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD. The trial, conducted in collaboration with Massachusetts General Hospital, will compare AL001's pharmacokinetics in healthy subjects against existing lithium carbonate products. With topline data expected by year-end, the study seeks to demonstrate AL001's targeted effectiveness and reduced side effects, potentially transforming care for over 43 million affected Americans. This development follows promising preclinical results indicating better brain absorption of lithium and lower blood levels in mice.
Read more →ALZN▼ -18.8%on this news· ran to -34% by day 3
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro has launched its first Phase II clinical trial for AL001, targeting Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. This trial, conducted at Massachusetts General Hospital, aims to assess AL001's effectiveness in delivering lithium more effectively in the brain compared to traditional lithium products. Previous studies indicated that AL001 provides better brain absorption while minimizing systemic side effects. The results are expected by the end of the year, potentially offering a safer and more efficient treatment option for patients.
Read more →ALZN▼ -9.4%on this news· ran to -22% by day 3shared move
Alzamend Neuro Announces Reverse Stock Split
Alzamend Neuro, Inc. announced a one-for-nine reverse stock split effective May 12, 2025, to comply with Nasdaq's minimum bid price requirement. This action will reduce the number of outstanding shares while maintaining the par value. The company aims to enhance its market position and investor confidence amidst ongoing development of treatments for Alzheimer's and other disorders.
Read more →ALZN▼ -6.2%on this newsshared move
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
Alzamend Neuro has partnered with QMENTA to utilize AI-powered imaging in its Phase II clinical trials of AL001 at Massachusetts General Hospital. This collaboration aims to optimize the imaging workflow and enhance data management for the trials. AL001 is designed to improve lithium delivery in the brain, potentially offering safer treatment options for Alzheimer's and other psychiatric disorders.
Read more →ALZNAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Alzamend Neuro has announced the initiation of a Phase II clinical trial for AL001, aimed at treating Alzheimer's disease. The trial, set to begin in Q4 2025 at Massachusetts General Hospital, follows promising results from earlier studies. AL001 is designed to improve lithium delivery in the brain while minimizing side effects, potentially transforming treatment for Alzheimer's patients.
Read more →ALZN▲ +5%on this news
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro has announced the initiation of a Phase II clinical trial for AL001, aimed at treating major depressive disorder (MDD). The trial, set to begin in Q4 2025 at Massachusetts General Hospital, follows successful preliminary studies. AL001 is designed to improve lithium delivery in the brain while reducing systemic side effects, potentially transforming MDD treatment.
Read more →ALZNAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro, Inc. has announced the initiation date of a Phase II clinical trial for AL001, aimed at treating post-traumatic stress disorder (PTSD) at Massachusetts General Hospital. This trial follows successful preclinical work indicating that AL001 may allow for enhanced lithium delivery with reduced systemic side effects. The company aims to demonstrate AL001's effectiveness as a next-generation therapy, potentially easing treatment for over 9 million Americans suffering from PTSD. This initiative may also alleviate the complexities associated with traditional lithium monitoring, which could reshape treatment paradigms in the field.
Read more →About Alzamend Neuro, Inc.
Headquarters480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA, GA, 30326
Founded2016
BIOPHARMAWATCH ELITE PLUS
Trade the next ALZN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime